{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:45:01Z","timestamp":1795041901100,"version":"4.10.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02257-y","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:11:47Z","timestamp":1762945907000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Donidalorsen: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5","key":"2257_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","volume":"1","author":"BL Zuraw","year":"2013","unstructured":"Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458\u201367.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2257_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1398-9995.2011.02751.x","volume":"67","author":"M Cicardi","year":"2012","unstructured":"Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147\u201357.","journal-title":"Allergy"},{"issue":"7","key":"2257_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"4","key":"2257_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","volume":"12","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Bordone L, Revenko A, et al. Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema. J Allergy Clin Immunol Pract. 2024;12(4):911\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"13","key":"2257_CR5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJMoa1915035","volume":"383","author":"DM Cohn","year":"2020","unstructured":"Cohn DM, Viney NJ, Fijen LM, et al. Antisense inhibition of prekallikrein to control hereditary angioedema. N Engl J Med. 2020;383(13):1242\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"2257_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/nat.2018.0754","volume":"29","author":"JD Ferrone","year":"2019","unstructured":"Ferrone JD, Bhattacharjee G, Revenko AS, et al. IONIS-PKKRx a novel antisense inhibitor of prekallikrein and bradykinin production. Nucleic Acid Ther. 2019;29(2):82\u201391.","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"2257_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2018.0753","volume":"29","author":"ST Crooke","year":"2019","unstructured":"Crooke ST, Baker BF, Xia S, et al. Integrated assessment of the clinical performance of GalNAc3-conjugated 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides: i. human volunteer experience. Nucleic Acid Ther. 2019;29(1):16\u201332.","journal-title":"Nucleic Acid Ther"},{"key":"2257_CR8","unstructured":"Ionis Pharmaceuticals. DAWNZERA\u2122 (donidalorsen) approved in the US as first and only RNA-targeted prophylactic treatment for hereditary angioedema [media release]. 21 Aug 2025. https:\/\/ir.ionis.com\/."},{"key":"2257_CR9","unstructured":"US Food and Drug Administration. DAWNZERA\u2122 (donidalorsen) injection, for subcutaneous use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219407s000lbl.pdf. Accessed 2 Oct 2025."},{"key":"2257_CR10","unstructured":"Otsuka Pharmaceutical. European Medicines Agency commences review of donidalorsen in hereditary angioedema [media release]. 6 Jan 2025. http:\/\/www.otsuka.com."},{"key":"2257_CR11","unstructured":"European Commission. Community register of orphan medicinal products. 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/o2898.htm. Accessed 2 Oct 2025."},{"key":"2257_CR12","unstructured":"US Food and Drug Administration. Orphan Drug designations and approvals. 2023. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=961723. Accessed 2 Oct 2025."},{"key":"2257_CR13","unstructured":"Theratechnologies. Theratechnologies announces exclusive licensing agreement with Ionis to commercialize olezarsen and donidalorsen in Canada [media release]. 4 Dec 2024. http:\/\/www.theratech.com."},{"key":"2257_CR14","unstructured":"Ionis Pharmaceuticals. Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema [media release]. 18 Dec 2023. https:\/\/ir.ionis.com\/."},{"key":"2257_CR15","unstructured":"Ionis Pharmaceuticals. Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema [media release]. 18 Jun 2024. http:\/\/www.ionis.com."},{"issue":"1","key":"2257_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Tachdjian R, Lumry WR, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391(1):21\u201331.","journal-title":"N Engl J Med"},{"issue":"11","key":"2257_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","volume":"386","author":"LM Fijen","year":"2022","unstructured":"Fijen LM, Riedl MA, Bordone L, et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med. 2022;386(11):1026\u201333.","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"2257_CR18","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.anai.2024.08.104","volume":"133","author":"P Singh","year":"2024","unstructured":"Singh P, Witjes H, Kleijn H, et al. Donidalorsen exposure-response analysis: hereditary angioedema attack rate versus plasma prekallikrein concentration relationship [abstract no. R073]. Ann Allergy Asthma Immunol. 2024;133(Suppl 6):S25.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl 2","key":"2257_CR19","doi-asserted-by":"publisher","first-page":"AB228","DOI":"10.1016\/j.jaci.2024.12.704","volume":"155","author":"H Khatri","year":"2025","unstructured":"Khatri H, Estepa P, Cummings B. Participant reported ease-of-use with a prefilled, single-dose, disposable autoinjector for the treatment of hereditary angioedema [abstract no. 699]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB228.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2257_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/all.16563","volume":"80","author":"MA Riedl","year":"2025","unstructured":"Riedl MA, Yarlas A, Bordone L, et al. Patient-reported outcomes in the phase III OASIS-HAE study of donidalorsen for hereditary angioedema. Allergy. 2025;80(8):2361\u20138.","journal-title":"Allergy"},{"key":"2257_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.06.018","author":"MA Riedl","year":"2025","unstructured":"Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. 2025. https:\/\/doi.org\/10.1016\/j.jaip.2025.06.018.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl 6","key":"2257_CR22","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.anai.2024.08.140","volume":"133","author":"R Tachdjian","year":"2024","unstructured":"Tachdjian R, Riedl M, Bordone L, et al. Donidalorsen for hereditary angioedema: results from the OASISplus open-label extension study [abstract no. R110 plus Poster]. Ann Allergy Asthma Immunol. 2024;133(Suppl 6):S38.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"2257_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/all.15948","volume":"79","author":"RS Petersen","year":"2023","unstructured":"Petersen RS, Bordone L, Riedl MA, et al. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy. 2023;79(3):724\u201334.","journal-title":"Allergy"},{"issue":"Suppl 2","key":"2257_CR24","first-page":"AB213","volume":"155","author":"M Manning","year":"2025","unstructured":"Manning M, Bordone L, Cohn D, et al. Long-term analysis of the phase 2 open-label extension of donidalorsen in patients with hereditary angioedema [abstract no. 654 plus Poster]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB213.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 2","key":"2257_CR25","doi-asserted-by":"publisher","first-page":"AB193","DOI":"10.1016\/j.jaci.2024.12.604","volume":"155","author":"M Riedl","year":"2025","unstructured":"Riedl M, Bernstein J, Tachdjian R, et al. Patient-reported injection-site pain and treatment satisfaction after switching from long-term prophylaxis to donidalorsen for the treatment of hereditary angioedema: results from The OASISplus study [abstract no. 599 plus Poster]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB193.","journal-title":"J Allergy Clin Immunol"},{"issue":"S113","key":"2257_CR26","first-page":"149","volume":"79","author":"R Tachdjian","year":"2024","unstructured":"Tachdjian R, Riedl MA, Bordone L, et al. Long-term safety of donidalorsen for the treatment of hereditary angioedema: results from the phase 3 open-label extension OASISplus study [abstract no. 100146]. Allergy. 2024;79(S113):149\u201350.","journal-title":"Allergy"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02257-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:00Z","timestamp":1769849880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02257-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2257"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02257-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}